REGULATORY
Council Drafts Scheme to Provide Unapproved Drugs in Response to Infectious Disease Outbreaks in Developing Countries
The Cabinet Secretariat’s public-private council on measures against infectious diseases in developing countries approved at a meeting on February 22 a scheme to provide approved drugs for off-label use to people in developing countries where outbreaks of infectious diseases have…
To read the full story
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Health Minister Signals Early March Approval for iPSC Products
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





